Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. | Arthritis Research and Therapy Vol 5 No 1 Hochberg Commentary COX-2 where are we in 2003 Be strong and resolute continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients Marc C Hochberg Division of Rheumatology and Clinical Immunology University of Maryland School of Medicine Baltimore Maryland USA Corresponding author Marc C Hochberg e-mail mhochber@ Received 31 October 2002 Accepted 14 November 2002 Published 11 December 2002 Arthritis Res Ther 2003 5 28-31 DOI ar617 2003 BioMed Central Ltd Print ISSN 1478-6354 Online ISSN 1478-6362 See related commentaries pages 5 8 and 25 Abstract Cyclooxygenase COX -2 selective inhibitors have been shown to have comparable efficacy to nonselective nonsteroidal anti-inflammatory drugs NSAIDs in the treatment of patients with osteoarthritis OA and rheumatoid arthritis RA . Large outcome studies have shown that patients with OA and RA not taking low-dose aspirin have fewer symptomatic and complicated upper GI events when treated with COX-2 selective inhibitors than with nonselective NSAIDs. When used in recommended dosages there is no convincing evidence that patients treated with COX-2 selective inhibitors have an increased incidence of cardiovascular thrombotic events including non-fatal myocardial infarction than patients treated with either placebo or nonselective NSAIDs other than naproxen. Co-therapy with low-dose aspirin is recommended in patients with OA and RA at increased risk for cardiovascular events the need for gastroprotective therapy in such patients is controversial. Keywords celecoxib COX-2 selective inhibitors osteoarthritis rheumatoid arthritis rofecoxib Introduction Nonsteroidal anti-inflammatory drugs NSAIDs are the cornerstone of therapy for relief of pain and inflammation in patients with acute and chronic musculoskeletal diseases particularly osteoarthritis OA and rheumatoid arthritis RA . The use of these drugs is limited however primarily by their .
